Bessemer Group Inc. Has $997,000 Stake in Luminex Co. (LMNX)

Bessemer Group Inc. cut its position in Luminex Co. (NASDAQ:LMNX) by 22.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,600 shares of the medical instruments supplier’s stock after selling 14,400 shares during the period. Bessemer Group Inc.’s holdings in Luminex were worth $997,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its stake in shares of Luminex by 1.3% in the second quarter. The Manufacturers Life Insurance Company now owns 31,640 shares of the medical instruments supplier’s stock worth $668,000 after purchasing an additional 402 shares in the last quarter. New York State Common Retirement Fund grew its stake in Luminex by 1.4% during the second quarter. New York State Common Retirement Fund now owns 44,200 shares of the medical instruments supplier’s stock valued at $934,000 after acquiring an additional 599 shares in the last quarter. Voya Investment Management LLC grew its stake in Luminex by 1.9% during the second quarter. Voya Investment Management LLC now owns 92,553 shares of the medical instruments supplier’s stock valued at $1,955,000 after acquiring an additional 1,737 shares in the last quarter. Legal & General Group Plc grew its stake in Luminex by 3.3% during the third quarter. Legal & General Group Plc now owns 78,767 shares of the medical instruments supplier’s stock valued at $1,602,000 after acquiring an additional 2,523 shares in the last quarter. Finally, Thrivent Financial For Lutherans grew its stake in Luminex by 14.4% during the second quarter. Thrivent Financial For Lutherans now owns 24,170 shares of the medical instruments supplier’s stock valued at $510,000 after acquiring an additional 3,050 shares in the last quarter. 76.34% of the stock is owned by hedge funds and other institutional investors.

In related news, Director G Walter Loewenbaum II sold 50,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $21.79, for a total transaction of $1,089,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 131,698 shares of company stock valued at $2,761,201 over the last ninety days. 6.90% of the stock is currently owned by corporate insiders.

Several equities analysts recently weighed in on LMNX shares. TheStreet raised shares of Luminex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 1st. BTIG Research started coverage on shares of Luminex in a research note on Friday, January 5th. They set a “buy” rating and a $24.00 target price for the company. Jefferies Group reaffirmed a “hold” rating and set a $21.00 target price on shares of Luminex in a research note on Friday, October 20th. Finally, BidaskClub raised shares of Luminex from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $22.33.

Luminex Co. (NASDAQ LMNX) opened at $18.77 on Friday. The firm has a market cap of $852.45, a price-to-earnings ratio of 28.44, a P/E/G ratio of 1.85 and a beta of 0.13. Luminex Co. has a 52 week low of $17.68 and a 52 week high of $22.42.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be paid a dividend of $0.06 per share. The ex-dividend date is Thursday, March 22nd. This represents a $0.24 annualized dividend and a yield of 1.28%. Luminex’s payout ratio is 36.36%.

COPYRIGHT VIOLATION WARNING: This piece was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2018/02/09/bessemer-group-inc-has-997000-stake-in-luminex-co-lmnx.html.

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply